History
Starting in January 2015, the member companies will be documenting the relevant data. In 2016, the first disclosure will occur – based on the year 2015. The disclosures will be made available also on the websites of the member companies.
Consistent advancement
The collaboration of the pharmaceutical industry with healthcare professionals is a decisive factor towards improving the care of patients. In order to guarantee that the patient's well-being is always the focus of any cooperation, the pharmaceutical industry established codes of conduct that create a transparent and ethically-sound basis for collaboration.
The voluntary self-regulation was successful up to now; however, societal expectations are continually increasing. In particular, the expectations for transparency of the system are rising.
The pharmaceutical industry is responding to this development by becoming increasingly more transparent and endeavouring to make its activity as perceptible as possible, in order to thus foster a better understanding of the collaboration between pharmaceutical companies and healthcare professionals: After all, those who have nothing to hide, have nothing to fear from transparency.
More information for disclosure:
Milestones
For the fourth year in a row, the pharmaceutical industry in Europe has announced its disclosure of value.
In June 2019, for the fourth year in a row, the pharmaceutical industry in Europe disclosed the transfer of value by pharmaceutical companies to medical professionals and healthcare organizations in the country. The disclosure of transfer of value is, on the one hand, for research and development, and on the other hand, to support the participation and organization of scientific and educational events such as seminars, conferences and congresses.
Terms and conditions of disclosure are set forth in the Disclosure Code of the European Federation of Pharmaceutical Industries and Associations. Bulgaria as a member of the European family is part of this process.
Over 66% of the healthcare professionals in Bulgaria have consented to disclosing their cooperation with pharmaceutical companies within the initiative “Transparency Builds Trust”
In June 2017 for a second consecutive year the pharmaceutical industry in Europe disclosed the transfers of value for research and development activities as well as transfers of value to healthcare specialists and their professional organizations – supporting and organizing scientific and education events, registration fees, lecturer fees.
Terms and conditions of disclosure are set forth in the Code of Disclosure of the European Federation of Pharmaceutical Industries and Associations and the relevant National code of ARPharM. Bulgaria as a member of the European family is part of this process.
Over 60% of the healthcare professionals in Bulgaria have consented to disclosing their cooperation with pharmaceutical companies within the initiative “Transparency builds trust”
On 28.06.2016 the Association of Research-Based Pharmaceutical Companies in Bulgaria (ARPharM) held an information meeting with representatives of the media. It is on the occasion of the forthcoming publication of the data provided in the Disclosure Code on Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations.
In June 2016 the R&D pharmaceutical industry in Europe will announce the transfers of value for research and development activities as well as transfers of value to healthcare specialists and their professional organizations – supporting and organizing scientific and education events, registration fees, lecturer fees. Terms and conditions of disclosure are set forth in the Code of Disclosure of the European Federation of Pharmaceutical Industries and Associations and the relevant National code of ARPharM. Bulgaria as a member of the European family is part of this process.
ARPharM adopted the Code for Disclosure of Transfers of Value by Pharmaceutical Companies to Healthcare Professionals and Health Organizations
On November 26, 2013 the Association of Research- based Pharmaceutical Manufacturers in Bulgaria (ARPharM) adopted the Code for Disclosure of Transfers of Value by Pharmaceutical Companies to Healthcare Professionals and Health Organizations. The new Code requires from the beginning of 2016 all members of the organization to publicly disclose their financial relationships with healthcare professionals and health organizations. Thereby ARPharM joined the initiative of the European Federation of Pharmaceutical Industries and Associations, which adopted its Disclosure Code in June 2013.
On June 24, 2013, the EFPIA General Assembly formally adopted the EFPIA Disclosure Code.
In adopting the Code, EFPIA member companies are required to implement it by 2016, at which point they will make publicly available payments and transfers of value made to healthcare professionals and organisations from the previous year, 2015.
